Literature DB >> 12176858

Vaccines against dangerous pathogens.

E D Williamson1, R W Titball.   

Abstract

Dangerous pathogens are defined by the UK Health and Safety Executive's advisory committee as category 3 (those which cause severe human disease for which prophylaxis or therapy is usually available) or category 4 (as for category 3, but for which prophylaxis or therapy is not available). Research and development of vaccines for such pathogens is challenging, due to the safety constraints in the manipulation of these pathogens. This chapter discusses the various approaches which can be taken to develop candidate vaccines for these pathogens, including the potential impact of genome sequencing on shortening the time required for R&D. For these pathogens, a direct test of the efficacy of the candidate vaccines in man is not ethical and, therefore, particular emphasis is placed on the demonstration of efficacy in animal models. Emphasis is also placed on the derivation of surrogate markers of efficacy and a demonstration that these correlate with protection in the animal model.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12176858     DOI: 10.1093/bmb/62.1.163

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  6 in total

1.  Administration of antibody to the lung protects mice against pneumonic plague.

Authors:  Jim Hill; Jim E Eyles; Stephen J Elvin; Gareth D Healey; Roman A Lukaszewski; Richard W Titball
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Repertoire of HLA-DR1-restricted CD4 T-cell responses to capsular Caf1 antigen of Yersinia pestis in human leukocyte antigen transgenic mice.

Authors:  Julie A Musson; Rebecca Ingram; Guillaume Durand; Stephanie Ascough; Emma L Waters; M Gillian Hartley; Timothy Robson; Bernard Maillere; E Diane Williamson; Shiranee Sriskandan; Daniel Altmann; John H Robinson
Journal:  Infect Immun       Date:  2010-07-26       Impact factor: 3.441

3.  Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts.

Authors:  Philip A Arlen; Michael Singleton; Jeffrey J Adamovicz; Yi Ding; Abdolreza Davoodi-Semiromi; Henry Daniell
Journal:  Infect Immun       Date:  2008-05-27       Impact factor: 3.441

Review 4.  Plague vaccines: current developments and future perspectives.

Authors:  Valentina A Feodorova; Vladimir L Motin
Journal:  Emerg Microbes Infect       Date:  2012-11-07       Impact factor: 7.163

5.  TRIF is a critical negative regulator of TLR agonist mediated activation of dendritic cells in vivo.

Authors:  Sergey S Seregin; Yasser A Aldhamen; Daniel M Appledorn; Charles F Aylsworth; Sarah Godbehere; Chyong-Jy Joyce Liu; Dionisia Quiroga; Andrea Amalfitano
Journal:  PLoS One       Date:  2011-07-08       Impact factor: 3.240

6.  Comprehensive Analysis of the Safety Profile of a Single-Stranded RNA Nano-Structure Adjuvant.

Authors:  Hyeong-Jun Park; Hae Li Ko; Dong-Hoon Won; Da-Bin Hwang; Yoo-Sub Shin; Hye-Won Kwak; Hye-Jung Kim; Jun-Won Yun; Jae-Hwan Nam
Journal:  Pharmaceutics       Date:  2019-09-07       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.